C S Cleeland1. 1. Department of Symptom Research, Division of Anesthesiology and Critical Care, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. ccleeland@mdanderson.org
Abstract
UNLABELLED: Routine and standardized assessment of pain should be conducted in patients with conditions, such as Fabry disease, that are associated with chronic pain. Such pain assessments, using validated and reliable pain scales or questionnaires, should cover the severity, location, temporal pattern and quality of the pain and how the pain impacts on quality of life and normal daily activity. The severity or intensity of pain can be assessed on verbal descriptor scales, visual analogue scales and numerical rating scales, which rate pain on a scale from 'no pain' through to 'excruciating pain' or pain as bad as you can imagine'. Three pain questionnaires that include such rating scales are short enough to be used repeatedly in a clinical or research setting: the Memorial Pain Assessment Card, the McGill Pain Questionnaire and the Brief Pain Inventory (BPI). The BPI also measures the effect of pain on daily activity and quality of life, defines the location of pain and assesses the effectiveness of previous pain relief medication. CONCLUSIONS: Reliable instruments are available to assess pain in chronic disease. In Fabry disease, these should be used routinely to aid decisions concerning analgesic/pain control medication and to assess the effect of enzyme replacement therapy.
UNLABELLED: Routine and standardized assessment of pain should be conducted in patients with conditions, such as Fabry disease, that are associated with chronic pain. Such pain assessments, using validated and reliable pain scales or questionnaires, should cover the severity, location, temporal pattern and quality of the pain and how the pain impacts on quality of life and normal daily activity. The severity or intensity of pain can be assessed on verbal descriptor scales, visual analogue scales and numerical rating scales, which rate pain on a scale from 'no pain' through to 'excruciating pain' or pain as bad as you can imagine'. Three pain questionnaires that include such rating scales are short enough to be used repeatedly in a clinical or research setting: the Memorial Pain Assessment Card, the McGill Pain Questionnaire and the Brief Pain Inventory (BPI). The BPI also measures the effect of pain on daily activity and quality of life, defines the location of pain and assesses the effectiveness of previous pain relief medication. CONCLUSIONS: Reliable instruments are available to assess pain in chronic disease. In Fabry disease, these should be used routinely to aid decisions concerning analgesic/pain control medication and to assess the effect of enzyme replacement therapy.
Authors: Melissa P Wasserstein; Simon A Jones; Handrean Soran; George A Diaz; Natalie Lippa; Beth L Thurberg; Kerry Culm-Merdek; Elias Shamiyeh; Haig Inguilizian; Gerald F Cox; Ana Cristina Puga Journal: Mol Genet Metab Date: 2015-05-30 Impact factor: 4.797
Authors: Joanna Ghali; Kathy Nicholls; Charles Denaro; David Sillence; Ian Chapman; Jack Goldblatt; Mark Thomas; Janice Fletcher Journal: JIMD Rep Date: 2011-09-15
Authors: Dawn Alyssia Laney; Daniel J Gruskin; Paul M Fernhoff; Joseph F Cubells; Opal Y Ousley; Heather Hipp; Ami J Mehta Journal: J Inherit Metab Dis Date: 2010-01-20 Impact factor: 4.982
Authors: Uma Ramaswami; Donald E Stull; Rossella Parini; Guillem Pintos-Morell; Catharina Whybra; Gisela Kalkum; Marianne Rohrbach; Mireia Raluy-Callado; Michael Beck; Wen-Hung Chen; Ingela Wiklund Journal: Health Qual Life Outcomes Date: 2012-09-20 Impact factor: 3.186
Authors: Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto Journal: J Bras Nefrol Date: 2022 Apr-Jun
Authors: Melissa P Wasserstein; George A Diaz; Robin H Lachmann; Marie-Hélène Jouvin; Indrani Nandy; Allena J Ji; Ana Cristina Puga Journal: J Inherit Metab Dis Date: 2018-01-05 Impact factor: 4.982